PubMed HealthSearch

PubMed · 10028140

A regression model for multivariate random length data.

Abstract

Multivariate random length data occur when we observe multiple measurements of a quantitative variable and the variable number of these measurements is also an observed outcome for each experimental unit. For example, for a patient with coronary artery disease, we may observe a number of lesions in that patient's coronary arteries, along with percentage of blockage of each lesion. Barnhart and Sampson first proposed the multiple population model to analyse multivariate random length data without covariates. This paper extends their approach to deal with multiple covariates. We propose a new multiple population regression model with covariates, and discuss the estimation issues. We analyse data from the TYPE II coronary intervention study to illustrate the methodology.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H X Barnhart, A S Kosinski, A R Sampson. 1999-01-30. A regression model for multivariate random length data.. https://doi.org/10.1002/(sici)1097-0258(19990130)18%3A2%3C199%3A%3Aaid-sim1%3E3.0.co%3B2-e

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

The pharmacoeconomic benefits of cholesterol reduction.

Recent studies show that cholesterol-lowering therapy can reduce morbidity and mortality in hypercholesterolemic patients without preexisting coronary heart disease (primary prevention) and with coronary heart disease (secondary prevention). The high cost of treatment per event prevented, especially for primary prevention, raises concerns about widespread use of cholesterol-lowering therapy. Does cholesterol reduction reduce utilization of healthcare resources, and can society afford to pay for reducing cholesterol in all patients with hypercholesterolemia, irrespective of risk factors? Is cost-effectiveness of therapy affected by differing cholesterol levels, age of the patients, the duration of therapy, or the presence of risk factors? Current pharmacoeconomic studies support the use of the statins for secondary prevention, and primary prevention in high-risk patients, and provide key information for policy decision making in the treatment of patients with hypercholesterolemia.

Cholestyramine Resin